Cargando…
The Perception among Israeli Gastroenterologists Regarding Treatment of Patients with Biosimilar Medications
Background and Objectives: The ever-expanding entry of biosimilar drugs into the Israeli market requires doctors to decide whether to prescribe these medications. We aimed to assess the prevalence of biosimilar use and Israeli gastroenterologists’ knowledge, experience, and perception of biosimilar...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10059953/ https://www.ncbi.nlm.nih.gov/pubmed/36984524 http://dx.doi.org/10.3390/medicina59030523 |
_version_ | 1785016998720176128 |
---|---|
author | Richter, Vered Cohen, Daniel L. Bermont, Anton Shalem, Tzippi Broide, Efrat Shirin, Haim |
author_facet | Richter, Vered Cohen, Daniel L. Bermont, Anton Shalem, Tzippi Broide, Efrat Shirin, Haim |
author_sort | Richter, Vered |
collection | PubMed |
description | Background and Objectives: The ever-expanding entry of biosimilar drugs into the Israeli market requires doctors to decide whether to prescribe these medications. We aimed to assess the prevalence of biosimilar use and Israeli gastroenterologists’ knowledge, experience, and perception of biosimilar treatment. Materials and Methods: A cross-sectional survey was conducted among Israeli Gastroenterology Association (IGA) members between March and May 2022 using a structured 20-item questionnaire. Results: The questionnaire was completed by 108 gastroenterologists. Sixty-two percent prescribed biosimilars to their patients in the past year. Most of the patients (81%) were biologically naïve and only 19% were switched to a biosimilar. Most gastroenterologists (75%) answered that the effectiveness is the same. The rates of resistance to switching were 19%, 36%, and 70% for patients in remission for over two years, pregnant women, and difficulty reaching remission, respectively. In cases seeing a lack of response after switching, most physicians chose to change the mechanism of action, with only a small percentage returning to the brand-name drug. Conclusions: Most Israeli gastroenterologists are not concerned about biosimilars’ safety and efficacy. Despite this, most physicians will prefer the brand-name drug, especially regarding adalimumab. The populations in which physicians most oppose switching are those who have had difficulty achieving remission and pregnant women. |
format | Online Article Text |
id | pubmed-10059953 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-100599532023-03-30 The Perception among Israeli Gastroenterologists Regarding Treatment of Patients with Biosimilar Medications Richter, Vered Cohen, Daniel L. Bermont, Anton Shalem, Tzippi Broide, Efrat Shirin, Haim Medicina (Kaunas) Article Background and Objectives: The ever-expanding entry of biosimilar drugs into the Israeli market requires doctors to decide whether to prescribe these medications. We aimed to assess the prevalence of biosimilar use and Israeli gastroenterologists’ knowledge, experience, and perception of biosimilar treatment. Materials and Methods: A cross-sectional survey was conducted among Israeli Gastroenterology Association (IGA) members between March and May 2022 using a structured 20-item questionnaire. Results: The questionnaire was completed by 108 gastroenterologists. Sixty-two percent prescribed biosimilars to their patients in the past year. Most of the patients (81%) were biologically naïve and only 19% were switched to a biosimilar. Most gastroenterologists (75%) answered that the effectiveness is the same. The rates of resistance to switching were 19%, 36%, and 70% for patients in remission for over two years, pregnant women, and difficulty reaching remission, respectively. In cases seeing a lack of response after switching, most physicians chose to change the mechanism of action, with only a small percentage returning to the brand-name drug. Conclusions: Most Israeli gastroenterologists are not concerned about biosimilars’ safety and efficacy. Despite this, most physicians will prefer the brand-name drug, especially regarding adalimumab. The populations in which physicians most oppose switching are those who have had difficulty achieving remission and pregnant women. MDPI 2023-03-07 /pmc/articles/PMC10059953/ /pubmed/36984524 http://dx.doi.org/10.3390/medicina59030523 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Richter, Vered Cohen, Daniel L. Bermont, Anton Shalem, Tzippi Broide, Efrat Shirin, Haim The Perception among Israeli Gastroenterologists Regarding Treatment of Patients with Biosimilar Medications |
title | The Perception among Israeli Gastroenterologists Regarding Treatment of Patients with Biosimilar Medications |
title_full | The Perception among Israeli Gastroenterologists Regarding Treatment of Patients with Biosimilar Medications |
title_fullStr | The Perception among Israeli Gastroenterologists Regarding Treatment of Patients with Biosimilar Medications |
title_full_unstemmed | The Perception among Israeli Gastroenterologists Regarding Treatment of Patients with Biosimilar Medications |
title_short | The Perception among Israeli Gastroenterologists Regarding Treatment of Patients with Biosimilar Medications |
title_sort | perception among israeli gastroenterologists regarding treatment of patients with biosimilar medications |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10059953/ https://www.ncbi.nlm.nih.gov/pubmed/36984524 http://dx.doi.org/10.3390/medicina59030523 |
work_keys_str_mv | AT richtervered theperceptionamongisraeligastroenterologistsregardingtreatmentofpatientswithbiosimilarmedications AT cohendaniell theperceptionamongisraeligastroenterologistsregardingtreatmentofpatientswithbiosimilarmedications AT bermontanton theperceptionamongisraeligastroenterologistsregardingtreatmentofpatientswithbiosimilarmedications AT shalemtzippi theperceptionamongisraeligastroenterologistsregardingtreatmentofpatientswithbiosimilarmedications AT broideefrat theperceptionamongisraeligastroenterologistsregardingtreatmentofpatientswithbiosimilarmedications AT shirinhaim theperceptionamongisraeligastroenterologistsregardingtreatmentofpatientswithbiosimilarmedications AT richtervered perceptionamongisraeligastroenterologistsregardingtreatmentofpatientswithbiosimilarmedications AT cohendaniell perceptionamongisraeligastroenterologistsregardingtreatmentofpatientswithbiosimilarmedications AT bermontanton perceptionamongisraeligastroenterologistsregardingtreatmentofpatientswithbiosimilarmedications AT shalemtzippi perceptionamongisraeligastroenterologistsregardingtreatmentofpatientswithbiosimilarmedications AT broideefrat perceptionamongisraeligastroenterologistsregardingtreatmentofpatientswithbiosimilarmedications AT shirinhaim perceptionamongisraeligastroenterologistsregardingtreatmentofpatientswithbiosimilarmedications |